Bronchiectasis in the Last Five Years: New Developments
AbstractBronchiectasis, a chronic lung disease characterised by cough and purulent sputum, recurrent infections, and airway damage, is associated with considerable morbidity and mortality. To date, treatment options have been limited to physiotherapy to clear sputum and antibiotics to treat acute infections. Over the last decade, there has been significant progress in understanding the epidemiology, pathophysiology, and microbiology of this disorder. Over the last five years, methods of assessing severity have been developed, the role of macrolide antibiotic therapy in reducing exacerbations cemented, and inhaled antibiotic therapies show promise in the treatment of chronic Pseudomonas aeruginosa infection. Novel therapies are currently undergoing Phase 1 and 2 trials. This review aims to address the major developments within the field of bronchiectasis over this time. View Full-Text
Share & Cite This Article
Khoo, J.K.; Venning, V.; Wong, C.; Jayaram, L. Bronchiectasis in the Last Five Years: New Developments. J. Clin. Med. 2016, 5, 115.
Khoo JK, Venning V, Wong C, Jayaram L. Bronchiectasis in the Last Five Years: New Developments. Journal of Clinical Medicine. 2016; 5(12):115.Chicago/Turabian Style
Khoo, Jun K.; Venning, Victoria; Wong, Conroy; Jayaram, Lata. 2016. "Bronchiectasis in the Last Five Years: New Developments." J. Clin. Med. 5, no. 12: 115.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.